Semaglutide helps reverse non-alcoholic fatty liver disease, study suggests
Outcomes were similar regardless of obesity status.
Semaglutide may double the resolution rate of non-alcoholic fatty liver disease in patients with stage 2 or 3 fibrosis, a Novo Nordisk-funded study across 37 countries suggests.
The phase III trial interim results covered 534 patients given once-weekly semaglutide 2.4mg and 270 given placebo, with both offered lifestyle counselling and management of comorbid conditions.
